Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 25, 2015 4:24 PM ET

Biotechnology

Company Overview of Stellar Biotechnologies, Inc.

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pha...

332 East Scott Street

Port Hueneme, CA 93041

United States

23 Employees

Phone:

805-488-2800

Fax:

805-488-2889

Key Executives for Stellar Biotechnologies, Inc.

Chairman, Chief Executive Officer and President
Age: 63
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secretary
Age: 56
Total Annual Compensation: $175.0K
Chief Operating Officer
Age: 40
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.

Stellar Biotechnologies, Inc. Key Developments

Stellar Biotechnologies Seeks Acquisitions

Stellar Biotechnologies, Inc. (TSXV:KLH) filed a shelf registration in the amount of $100 million and will use the proceeds of the offering to in-license, acquire or invest in complementary businesses, technologies, products or assets

Stellar Biotechnologies Enters into Expanded Supply Agreement with Neovacs

Stellar Biotechnologies, Inc. and Neovacs S.A. have entered into an expanded supply agreement, under which Stellar will supply its Keyhole Limpet Hemocyanin, or KLH, for Neovacs's proprietary Kinoid immunotherapy technology. The new agreement extends and expands the supply contracts previously in place between the Companies, in order to ensure the continued supply of Stellar KLH to Neovacs during its Kinoid clinical trials and to support the expected commercial roll-out of Neovacs' lead product candidate IFNalpha-Kinoid, an immunotherapy being developed for the treatment of systemic lupus erythematosus ("lupus").

Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship

Stellar Biotechnologies, Inc. and Neovacs S.A. announced that the companies have entered into an expanded supply agreement to meet Neovacs' requirements for Keyhole Limpet Hemocyanin. The new agreement extends and expands the supply contracts previously in place between the Companies, in order to ensure the continued supply of Stellar KLH to Neovacs during its Kinoid clinical trials and to support the expected commercial roll-out of Neovacs' lead product candidate IFN?-Kinoid, an immunotherapy being developed for the treatment of systemic lupus erythematosus. Stellar is a leader in the sustainable manufacture of KLH, an immune-stimulating protein widely used as a carrier molecule in immuno therapies under development for a variety of disease indications. Immunotherapy uses a patient's own immune system to target and treat diseases. KLH can only be produced from a scarce marine source. Stellar believes it is the only company with the proprietary technology to manage sustainable, scalable production of GMP quality KLH to meet future pharmaceutical industry demands. Neovacs is a leader in the development of active immuno therapies for the treatment of chronic autoimmune diseases. Neovacs' patented Kinoid technology combines a select cytokine of interest attached to KLH as the immune-stimulating carrier protein. The resulting immunotherapy uses the patient's immune system to generate antibodies against the targeted disease. This phase IIb study is expected to begin mid-2015. A U.S. Phase IIa trial of IFN-Kinoid for the treatment of lupus in the U.S. is expected to commence by early 2016. Under the terms of the agreement, Neovacs will purchase Stellar KLH for use in its proprietary KLH-based Kinoid immunotherapies in the European Union, Latin America, Asia, the U.S. and Canada. Neovacs will use Stellar KLH for its planned Phase II and Phase III clinical trials and for expected commercial manufacturing of its products for up to one year following market approval. Neovacs will manage and fund all product development and regulatory submissions for its immunotherapy products and act as the sponsor company for the future clinical trials. Stellar will supply GMP grade KLH to Neovacs according to agreed specifications, quantities, and pricing, as well as maintain a master file with the U.S. FDA for the KLH product. Stellar will also provide professional, technical, and regulatory support to Neovacs. The agreement has an initial five-year term, which may be renewed by Neovacs in one-year increments.

Similar Private Companies By Industry

Company Name Region
Biotage, LLC United States
Hitachi Chemical Research Center, Inc. United States
Aldevron, LLC United States
Ala Wai Pharma, Inc. United States
Vedantra Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Stellar Biotechnologies, Inc., please visit www.stellarbiotechnologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.